CellPoint Chief Financial Officer Terry Colip said the company is aiming for commercialization of its SPECT agent EC-G in 2013. In March, the company received FDA approval for a Phase III lung cancer trial. The agent is in a Phase II clinical study involving patients with coronary artery disease. CellPoint officials say the agent will offer a lower-cost diagnostic technique.
Published in Brief: